Biopharma M&A: Lessons From 2019, Trends For 2020
Deals Integral To Sector's Development
“Growth gaps” were the driver for a record-breaking M&A year – but CEOs must remain disciplined when pursuing opportunities, or pay the price down the line.
You may also be interested in...
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.
Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.